AO: The analyst cites STS work that has been concerned with the translational research that makes medical discoveries in the lab turn into medical interventions at the bedsite.
AO: The analyst mentions discussions of “efficacy” as shaping the conversations about the production of the HPV vaccine. Some authors cited argued that if scientists been instilled with “social aims of efficiency in disease reduction” rather than “clincal trial efficacy”, scientists could have drawn from a universe of possible vaccine technologies that were cheaper, shelf-stable, and thus more likely to reduce the burden of cervical cancer among the poor (4). Analyst argues that historical evidence suggests that the NCI scientists responsible for the basic research that developed the vaccine did not ignore efficiency for the sake of efficacy and actually actively strove to balance efficacy with efficiency.
